Artivion Inc.

History

Year	Detail
1984	Founded in 1984, CryoLife was the first biomedical company to specialize in the low-temperature preservation of human heart valves used for complex cardiac reconstruction, primarily in children born with heart defects.
1996	The company acquired the initial patents and technology for a surgical adhesive, BioGlue, a protein hydrogel polymer, from its inventor, Nicholas Kowanko, Ph.D. After three years of product development and clinical testing, it received CE Mark approval for all European countries.
2002	The company signed agreements with AlloSource, a non-profit tissue bank cooperative. The agreement outlined CryoLife, Inc.'s distribution of AlloSource processed fresh osteoarticular (OA) grafts and fresh-frozen tibialis tendon allografts.
2005	CryoLife Inc. and Endologix Inc. signed a development and marketing agreement for the percutaneous or endovascular delivery of CryoLife's BioFoam, a self-expanding sealant for endovascular aortic aneurysm grafts.
2011	The company acquired Cardiogenesis Corporation, a developer of surgical products used in the treatment of patients with refractory angina resulting from diffuse coronary artery disease, for approximately $22 million in cash to expand its cardiac surgery portfolio.
2012	The company acquired Hemosphere, Inc., which developed and marketed the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.
2014	Cryolife acquired the distribution rights for the ProCol Vascular Bioprosthesis ("ProCol") from Hancock Jaffe Laboratories, Inc., for hemodialysis access for $2.3 million over five years.
2014	CryoLife acquired the distribution rights to PhotoFix, a bovine pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde from Genesee BioMedical, Inc., a Denver, Colorado-based manufacturer of cardiac surgery instruments and devices.
2016	The company acquired On-X Life Technologies Holdings Inc., a privately held mechanical heart valve company based in Austin, Texas, to expand its portfolio in the cardiovascular medical device industry.
2017	The company acquired JOTEC AG, a German-based, privately held developer of technologically differentiated endovascular stent grafts and cardiac and vascular surgical grafts focused on aortic repair, to expand its product offerings in the vascular and endovascular surgery markets and strengthen its presence in the European market.
2020	The company acquired Ascyrus Medical LLC (Ascyrus), a Florida-based, privately held developer of the Ascyrus Medical Dissection Stent (AMDS), the world's first aortic arch remodeling device used for the treatment of acute Type A aortic dissections to add the AMDS to CryoLife's product portfolio and further strengthen the company's position in the growing aortic repair market.
2022	The company transformed significantly by rebranding as Artivion Inc. Derived from the words "aorta," "innovation," and "vision," the company's new name and brand reflected its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease.